Non-Vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: The concept for a trial

Europace

Volumn 18, Issue 1, 2015, Pages 6-11

  De Caterina, Raffaele ^a,b   John Camm, A ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Artificial valve; Bioprosthetic valve; Mechanical valve; Mitral stenosis; NOACs; Non Vitamin K antagonist oral anticoagulants; Oral anticoagulants; Prosthetic valve; Rheumatic heart disease; Stroke; Thromboembolism; Valvular atrial fibrillation; Valvular heart disease; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DABIGATRAN ETEXILATE; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAZIL; CHINA; DRUG EFFICACY; DRUG SAFETY; EGYPT; FEASIBILITY STUDY; FOLLOW UP; HEART ATRIUM APPENDAGE; HEART ATRIUM CONTRACTION; HEART INFARCTION; HEART LEFT ATRIUM; HUMAN; INDIA; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MECHANICAL HEART VALVE; MEXICO; MITRAL VALVE STENOSIS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SAMPLE SIZE; SOUTH AFRICA; STUDY DESIGN; THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; COMPLICATION; EVIDENCE BASED MEDICINE; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; EVIDENCE-BASED MEDICINE; HUMANS; MITRAL VALVE STENOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84962019791     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv288     Document Type: Article

References (52)

1. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J 2011; 342: d124
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420
3. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillationdeveloped with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, HackeWet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92
7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104
8. Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of valvular and non-valvular atrial fibrillation: results of a physicians survey. Europace 2014; 16: 1720-5
9. De Caterina R, Camm AJ. What is valvular atrial fibrillation? A reappraisal. Eur Heart J 2014; 35: 3328-35
10. Wood P. An appreciation of mitral stenosis: II. Investigations and results. Br Med J 1954; 1: 1113-24
11. Wood P. An appreciation of mitral stenosis. I. Clinical features. Br Med J 1954; 1: 1051-63
12. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: ten-And twenty-year perspectives. Ann Intern Med 1960; 52: 741-9
13. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962; 24: 349-57
14. Abernathy WS, Willis PW III. Thromboembolic complications of rheumatic heart disease. Cardiovasc Clin 1973; 5: 131-75
15. Caplan LR, DCruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation, and stroke. Ann Neurol 1986; 19: 158-61
16. Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26: 2463-71
17. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-661
18. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96
19. Daley R, MattinglyTW, Holt CL, Bland EF, White PD. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951; 42: 566-81
20. Adams GF, Merrett JD, Hutchinson WM, Pollock AM. Cerebral embolism and mitral stenosis: survival with and without anticoagulants. J Neurol Neurosurg Psychiatry 1974; 37: 378-83
21. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102: 426S-33S
22. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-Term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25: 1354-61
23. You ZH, Yang WC, Chen JD, Lin CC. Giant atrial thrombus. Intern Med J 2011; 41: 67-8
24. Chakraborty P, Mukerjee S, Parashar SK, Yadav KG, Ranjan N. Giant left atrial thrombus with coronary arteriovenous fistula formation in patient with rheumatic mitral stenosis: a case report. Indian Heart J 2011; 63: 203
25. Judas T, Almeida AR, Celeiro MR, Cotrim C, Miranda R, Almeida S, et al. Giant left atrial thrombus: an unexpected finding. Rev Port Cardiol 2011; 30: 621-6
26. Lazar AA, Aszalos A, Ober C, Encica S, Scridon T, Iancu AC. A case of mobile giant left atrial thrombus which vascularized with coronary arteries in severe mitral valve stenosis, published in Cardiovascular Revascularization Medicine 2010; 11(2): 71-138. Cardiovasc Revasc Med 2011; 12: 235-6
27. Luis SA, Poon K, Luis C, Shukla A, Bett N, Hamilton-Craig C. Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran. Circ Cardiovasc Imaging 2013; 6: 491-2
28. Akcay M, Gulel O, Bahcivan M, Yuksel S. Double giant thrombi in the left atrium in a patient with rheumatic mitral valve stenosis and atrial fibrillation. Eur J Cardiothorac Surg 2013; 44: 1150
29. Peters F, Khandheria BK, Patel AR, Essop MR. Mitral stenosis and pedunculated left atrial thrombus: an unusual presentation. Eur Heart J Cardiovasc Imaging 2013; 14: 117
30. Rider OJ, Malhotra A, Newton JD. Free floating left atrial ball thrombus: a rare cause of stroke. J Stroke Cerebrovasc Dis 2013; 22: e238-239
31. Santos PM, Lopez EB, Barrio EE, Marrupe LH, Valtierra JJ, Gonzalez FP, et al. Massive left atrium thrombus. Int J Cardiovasc Imaging 2014; 30: 67
32. Undas A, Rozanska M, Stepien E, Pfitzner R, Sadowski J. Architecture of intra-Atrial thrombi in patients with severe mitral stenosis. J Heart Valve Dis 2009; 18: 496-8
33. Manjunath CN, Srinivasa KH, Panneerselvam A, Prabhavathi B, Ravindranath KS, Rangan K, et al. Incidence and predictors of left atrial thrombus in patients with rheumatic mitral stenosis and sinus rhythm: a transesophageal echocardiographic study. Echocardiography 2011; 28: 457-60
34. Krishnamoorthy KM. Incidence and predictors of left atrial thrombus in patients with rheumatic mitral stenosis and sinus rhythm: a transesophageal echocardiographic study. Echocardiography 2012; 29: 876-7
35. Rajappa M, Sunil Roy TN, Raj A, Trehan V, Mallika V. D-Dimer assay as a non invasive test for the diagnosis of left atrial Thrombi in Indian patients with Rheumatic MS. Afr Health Sci 2013; 13: 584-9
36. Ozturk D, CelikO, Akin F, Akturk F, Aslan S, Ozyilmaz SO, et al. Usefulness of the uric acid and CHA2DS2-VASC score in prediction of left atrial thrombosis in patients with mitral stenosis and sinus rhythm. Cardiol J 2014; doi: 10.5603/CJ.a2014.0059
37. World Health Organization-WHO. Rheumatic Fever and Rheumatic Heart Disease: Report of a WHO Expert Consultation, Geneva, 29 October-1 November 2001. Geneva: WHO
38. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-37
39. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83
40. Zuhlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015; 36: 1115-1122a
41. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67
42. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-98
43. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-75S
44. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-Term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503
45. van Es RF, Jonker JJ, VerheugtFW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109-13
46. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52
47. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H.Warfarin, aspirin, or both after myocardial infarction N Engl J Med 2002 347 969-74
48. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-107
49. Butchart E, De Caterina R. Antithrombotic management in patients with prothetic valves. In Moliterno D, Kristensen S, De Caterina R (eds). Therapeutic Advances in Thrombosis. New York: Wiley-Blackwell 2013. pp.246-270
50. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: e57-185
51. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-14
52. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17